Factors that impact on healthcare workers' adherence with infection prevention and control (IPC) guidelines for COVID-19: a qualitative evidence synthesis.

Cochrane Database Syst RevSep 1, 2026 (epub)
Clinical ResearchInfectious DiseasesPreventive Medicine / Public HealthOpen access

Catherine Houghton, Pauline Meskell, Hannah Delaney et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review synthesizes qualitative evidence on factors affecting healthcare workers' adherence to infection prevention and control (IPC) guidelines for COVID-19. It included 170 studies, analyzing 26 for insights across various healthcare settings and income levels. Key findings highlight the complex interplay of contextual factors influencing adherence, essential for improving IPC practices in future pandemics.

Key findings

  • Adherence to IPC guidelines is influenced by contextual factors unique to the COVID-19 pandemic.
  • The review included studies from ten Asian countries, eight African countries, and others from North America, South America, and Oceania.
  • Only 26 out of 170 eligible studies were analyzed for detailed insights.

Why it matters

Understanding the factors that impact adherence to IPC guidelines is crucial for healthcare systems to enhance safety protocols and protect both healthcare workers and patients during pandemics.

Source

PubMed · PMID 42677895Free full text on PubMed Central

Published in Cochrane Database Syst Rev. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Infectious Diseases

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.